HLA-A2 and/or DR4-positive RCC patients evaluated in this study
Individual SLR designations reflect specimen number based on date harvested. In 5 cases, both pre- and (6 weeks) post-therapy blood specimens were available for analysis, as indicated. Where indicated, the time of peripheral blood isolation (in months) post-therapy is provided. HLA-A2 and -DR4 status was determined using allele-specific monoclonal antibodies and flow cytometry gating on peripheral blood monocytes, as described in “Materials and Methods.” Immunohistochemical stained tumor biopsies were available from 14 patients and were stained for EphA2 expression as outlined in “Materials and Methods.” EphA2 expression is indicated on an arbitrary 0 to 4+ scale.
| RCC patient . | Age . | Sex . | Stage . | Treatment . | Disease status at time of evaluation (months) . | HLA typing . | . | Tumor expression EphA2 . | |
|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | A2 (+/−)/DR4 (+/−) . | . | . | |
| SLR30-pre | 63 | F | I | None | Local Dis. | + | − | NAa | |
| SLR31 | 66 | M | I | S | Local Dis. | + | − | 2+ | |
| SLR32 | 62 | F | I | S | Local Dis. | + | − | 2+ | |
| SLR33 | 54 | F | I | S | Local Dis. | + | − | 3+ | |
| SLR34 | 71 | M | I | None | Local Dis. | + | + | NA | |
| SLR35 | 75 | F | I | None | Local Dis. | + | + | NA | |
| SLR36-pre | 60 | M | I | None | Local Dis. | + | + | NA | |
| SLR37 | 52 | M | I | None | Local Dis. | + | − | NA | |
| SLR38-pre | 69 | M | I | None | Local Dis. | + | − | NA | |
| SLR39 | 65 | M | I | S | NED (3) | + | − | 3+ | |
| SLR30-post | 63 | F | I | S | NED (1.5) | + | − | NA | |
| SLR40 | 53 | M | I | S | NED (3) | + | − | NA | |
| SLR36-post | 60 | M | I | S | NED (2) | + | + | NA | |
| SLR41 | 64 | F | I | S | NED (2) | + | − | 2+ | |
| SLR38-post | 69 | M | I | S | NED (2) | + | − | 3+ | |
| SLR42 | 58 | F | I | S | Local Dis. (3) | + | − | 3+ | |
| SLR43 | 53 | F | I | S | Local Dis. (1.5) | + | − | 3+ | |
| SLR44-pre | 69 | M | IV | None | Mets. | + | − | NA | |
| SLR45 | 65 | M | IV | S | Mets | + | − | 4+ | |
| SLR46 | 45 | F | IV | S | Mets | + | − | 0 | |
| SLR47 | 53 | F | IV | S | NED (1.5) | + | − | NA | |
| SLR48 | 54 | M | IV | S | Mets. (61) | + | − | NA | |
| SLR49 | 52 | F | IV | S, R, IFN-α, IL-2 | Mets. (41) | + | − | 2+ | |
| SLR44-post | 69 | M | IV | S | Mets (2) | + | − | 4+ | |
| SLR50 | 54 | M | IV | S, R, C | Mets (21) | + | − | NA | |
| SLR51 | 41 | M | IV | S, R, IL-2 | Mets | + | + | NA | |
| SLR52 | 58 | M | IV | S, R, IFN-α | Mets | + | + | NA | |
| SLR53 | 52 | M | IV | S | Mets | + | − | NA | |
| SLR54 | 49 | F | IV | C, IL-2 | Mets | + | + | NA | |
| SLR55 | 79 | M | IV | C, IFN-α | Mets | + | + | NA | |
| SLR56 | 56 | M | IV | R, C, IFN-α, IL-2 | Mets | + | − | NA | |
| SLR57 | 68 | F | IV | S | Mets | + | − | 3+ | |
| SLR58 | 55 | F | IV | None | Mets | + | + | NA | |
| SLR59 | 52 | F | I | None | Local Dis. | − | + | NA | |
| SLR60-pre | 58 | M | I | None | Local Dis. | − | + | NA | |
| SLR61 | 60 | M | I | S | Local Dis. | − | + | 2+ | |
| SLR62 | 64 | M | I | S | NED (3) | − | + | NA | |
| SLR63 | 53 | F | I | S | NED (1.5) | − | + | NA | |
| SLR60-post | 58 | M | I | S | NED (2) | − | + | NA | |
| SLR64 | 65 | M | I | S | NED (10) | − | + | NA | |
| SLR65 | 53 | M | II | S | Local Dis. | − | + | NA | |
| SLR66 | 45 | M | IV | None | Mets. | − | + | NA | |
| SLR67 | 57 | M | IV | C, R | Mets | − | + | NA | |
| SLR68 | 69 | M | IV | S, R, C | Mets | − | + | NA | |
| SLR69 | 49 | M | IV | S, C, R, IFNα, IL-2 | Mets | − | + | NA | |
| RCC patient . | Age . | Sex . | Stage . | Treatment . | Disease status at time of evaluation (months) . | HLA typing . | . | Tumor expression EphA2 . | |
|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | A2 (+/−)/DR4 (+/−) . | . | . | |
| SLR30-pre | 63 | F | I | None | Local Dis. | + | − | NAa | |
| SLR31 | 66 | M | I | S | Local Dis. | + | − | 2+ | |
| SLR32 | 62 | F | I | S | Local Dis. | + | − | 2+ | |
| SLR33 | 54 | F | I | S | Local Dis. | + | − | 3+ | |
| SLR34 | 71 | M | I | None | Local Dis. | + | + | NA | |
| SLR35 | 75 | F | I | None | Local Dis. | + | + | NA | |
| SLR36-pre | 60 | M | I | None | Local Dis. | + | + | NA | |
| SLR37 | 52 | M | I | None | Local Dis. | + | − | NA | |
| SLR38-pre | 69 | M | I | None | Local Dis. | + | − | NA | |
| SLR39 | 65 | M | I | S | NED (3) | + | − | 3+ | |
| SLR30-post | 63 | F | I | S | NED (1.5) | + | − | NA | |
| SLR40 | 53 | M | I | S | NED (3) | + | − | NA | |
| SLR36-post | 60 | M | I | S | NED (2) | + | + | NA | |
| SLR41 | 64 | F | I | S | NED (2) | + | − | 2+ | |
| SLR38-post | 69 | M | I | S | NED (2) | + | − | 3+ | |
| SLR42 | 58 | F | I | S | Local Dis. (3) | + | − | 3+ | |
| SLR43 | 53 | F | I | S | Local Dis. (1.5) | + | − | 3+ | |
| SLR44-pre | 69 | M | IV | None | Mets. | + | − | NA | |
| SLR45 | 65 | M | IV | S | Mets | + | − | 4+ | |
| SLR46 | 45 | F | IV | S | Mets | + | − | 0 | |
| SLR47 | 53 | F | IV | S | NED (1.5) | + | − | NA | |
| SLR48 | 54 | M | IV | S | Mets. (61) | + | − | NA | |
| SLR49 | 52 | F | IV | S, R, IFN-α, IL-2 | Mets. (41) | + | − | 2+ | |
| SLR44-post | 69 | M | IV | S | Mets (2) | + | − | 4+ | |
| SLR50 | 54 | M | IV | S, R, C | Mets (21) | + | − | NA | |
| SLR51 | 41 | M | IV | S, R, IL-2 | Mets | + | + | NA | |
| SLR52 | 58 | M | IV | S, R, IFN-α | Mets | + | + | NA | |
| SLR53 | 52 | M | IV | S | Mets | + | − | NA | |
| SLR54 | 49 | F | IV | C, IL-2 | Mets | + | + | NA | |
| SLR55 | 79 | M | IV | C, IFN-α | Mets | + | + | NA | |
| SLR56 | 56 | M | IV | R, C, IFN-α, IL-2 | Mets | + | − | NA | |
| SLR57 | 68 | F | IV | S | Mets | + | − | 3+ | |
| SLR58 | 55 | F | IV | None | Mets | + | + | NA | |
| SLR59 | 52 | F | I | None | Local Dis. | − | + | NA | |
| SLR60-pre | 58 | M | I | None | Local Dis. | − | + | NA | |
| SLR61 | 60 | M | I | S | Local Dis. | − | + | 2+ | |
| SLR62 | 64 | M | I | S | NED (3) | − | + | NA | |
| SLR63 | 53 | F | I | S | NED (1.5) | − | + | NA | |
| SLR60-post | 58 | M | I | S | NED (2) | − | + | NA | |
| SLR64 | 65 | M | I | S | NED (10) | − | + | NA | |
| SLR65 | 53 | M | II | S | Local Dis. | − | + | NA | |
| SLR66 | 45 | M | IV | None | Mets. | − | + | NA | |
| SLR67 | 57 | M | IV | C, R | Mets | − | + | NA | |
| SLR68 | 69 | M | IV | S, R, C | Mets | − | + | NA | |
| SLR69 | 49 | M | IV | S, C, R, IFNα, IL-2 | Mets | − | + | NA | |
C, chemotherapy; IFN-α, recombinant IFN-α therapy; IL-2, recombinant interleukin-2 therapy; Mets, metastatic disease; NA, not available for evaluation; NED, no evidence of disease; R, radiotherapy; S, surgery.